(Q48832403)

English

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

scientific article published in October 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. (English)

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

hypercholesterolemia

0 references

author name string

Kostis JB

1

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

Rosen RC

2

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

Wilson AC

3

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

publication date

1 October 1994

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

34

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

989-996

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

10

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Beta-blockers and central nervous system side effects

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Depressive symptoms in hypercholesterolaemic patients treated with pravastatin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Depressive symptoms and cholesterol-lowering drugs

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1994.TB01971.X

21 January 2018

Identifiers

10.1002/J.1552-4604.1994.TB01971.X

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/7836550

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48832403&oldid=951774315"